Journal of the Korean Academy of Child and Adolescent Psychiatry : eISSN 2233-9183 / pISSN 1225-729X

Table. 1.

Table. 1.

Drugs with KMFDS approval for ADHD

 Generic name  Brand nameUsual daily dose, mg (mg/kg)*Duration of effect (hour)
Methylphenidate
 Methylphenidate IR Penid (T), perospin (T) 10-60 (0.3-1.5) 3–5
 Methylphenidate ER Metadate CD ER (C), medikinet retard (C) 20-60 (0.6-1.5) 6–8
 Methylphenidate OROS Concerta OROS ER (T) 18-72 (0.4-1.8) 12
Norepinephrine-reuptake inhibitor
 Atomoxetine Strattera (C), atomoxin (C), atocera (C), atomoxetine (C) 18-100 (0.7-1.4) At least 10–12
α2-Adrenergic agonists
 Clonidine ER Kapvay ER (T) 0.1-0.4 At least 10–12

usual dose should not be interpreted as a cap or a minimal effective dose if a higher or lower dose is clinically indicated in individual cases. ADHD:attention-deficit hyperactivity disorder, C:capsule, ER:extended release, IR:immediate release, KMFDS:Korean Ministry of Food and Drug Safety, OROS:osmotic controlled-release oral delivery system, T:tablet

J Korean Acad Child Adolesc Psychiatry 2017;28:70-83 https://doi.org/10.5765/jkacap.2017.28.2.70
© 2017 J Korean Acad Child Adolesc Psychiatry